Measurable residual disease (MRD) detection using next-generation sequencing (NGS) has allowed for a sensitive evaluation of a patient's relapse risk, but several challenges remain unresolved. Bulk NGS alone provides limited sensitivity and specificity to deconstruct the complex heterogeneity/somatic mosaicism driving disease transformation or to distinguish between leukemic clones and clonal hematopoiesis (CH). It also lacks information about immunophenotypic heterogeneity, typically inferred by flow cytometry, rendering an incomplete picture.
Mission Bio's Tapestri Platform is the first single-cell multi-omics approach integrating molecular (mutational) profiling and immunophenotyping in a single assay to allow for scMRD detection with unparalleled resolution, sensitivity and specificity, ultimately improving identification of residual disease and potential therapeutic strategies
Tapestri Platform resolves several challenges in MRD testing:
Unmask clonal architecture at diagnosis and during treatment and detect rare and subclonal variants driving the disease transformation
Characterize changes in clonal diversity over time, providing valuable information about tumor evolution and its correlation with relapse
Enable unambiguous distinction between leukemia driving clones and CH, reducing false positives
Integrate single-cell genotypic and immunophenotypic information for a comprehensive MRD assessment
Interested in learning more about our scMRD technology? Join us on August 16 in New York City for the Tapestri scMRD for AML Summit.
Mission Bio is now offering a Tapestri scMRD early access program to academic and translational research labs and pharmaceutical companies with acute myeloid leukemia (AML) samples. Sign up today to participate in the early access program.
